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Background: Rearrangements involving ETV6 (12p13) are among the most common structural abnormalities in pediatric
B-cell acute lymphoblastic leukemia (B-ALL) and involve numerous partner genes. Additionally, the t(8;14)(q11.2;q32), which
can result in the placement of CEBPD (8q11.2) near the regulatory regions of IGH@ (14q32) and consequent overexpression
of CEPBD, occurs at a higher frequency in individuals with Down syndrome-associated ALL (DS-ALL) compared to both the
general and pediatric population. The coexistence of cytogenetically detectable ETV6 abnormalities and t(8;14)(q11.2;q32) is
a rare occurrence in B-ALL and has only been reported in a single case in the literature.
Findings: Herein, we present a case of B-ALL in a 9-year old male with Down syndrome in which conventional cytogenetic
analysis revealed two reciprocal translocations: a t(8;14)(q11.2;q32) and a t(2;12)(p12;p13). Interphase and metaphase
fluorescence in situ hybridization (FISH) analysis using break apart probes confirmed the involvement of IGH@ and ETV6
in these translocations, respectively. Additionally, interphase FISH revealed a clonal subpopulation bearing biallelic IGH@
rearrangements not observed by conventional cytogenetic analysis.
Conclusions: To the best of our knowledge, this is the first reported case of B-ALL bearing an ETV6 translocation with
a partner gene on the short arm of chromosome 2 confirmed by FISH. Additionally, it is the second reported case of
t(8;14)(q11.2;q32)-ALL bearing a concomitant, cytogenetically detectable abnormality involving ETV6. This case provides
insight into a novel translocation involving ETV6 as well as potentially unique and understudied mechanisms of clonal
evolution in pediatric B-ALL.
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Pediatric B-acute lymphoblastic leukemia (B-ALL) often
bears a range of numerical and structural cytogenetic ab-
normalities, including but not limited to the following, in
decreasing frequency: t(12;21)(p13;q22) [ETV6/RUNX1],
hyperdiploidy, t(1;19)(q23;p13.3) [PBX1/TCF3], t(4;11)(q21;
q23) [AFF1/MLL], hypodiploidy, and t(9;22)(q34;q11.2)
[BCR/ABL1] [1]. Additionally, the t(8;14)(q11.2;q32), which
can result in the placement of CEBPD (8q11.2) near the
regulatory regions of IGH@ (14q32) and consequent over-
expression of CEPBD, occurs at a much higher frequency* Correspondence: ctirado@mednet.ucla.edu
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creativecommons.org/publicdomain/zero/1.0/in individuals with Down syndrome compared to both the
general and pediatric population and is associated with an
intermediate prognosis [2].
Rearrangements involving ETV6 (12p13) are among the
most common structural abnormalities in pediatric B-
ALL. The t(12;21)(p13;q22), the most common of these
translocations, results in the production of a chimeric
transcription factor bearing the DNA-binding domain of
RUNX1 (21q22) and the transactivation domain of ETV6
(12p13), resulting in aberrant activation of genes regulated
by RUNX1. Although the t(12;21) [ETV6/RUNX1] is the
most common of these rearrangements, other transloca-
tions involving ETV6 with greater than 20 partner genes
have been observed, including protein tyrosine kinasesticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tinct mechanisms to promote leukemogenesis [3]. Add-
itionally, other anomalies involving ETV6 have been
observed in various hematological malignancies ranging
from deletions, to point mutations, to alterations at the
epigenetic level, to amplifications [3–5]. Although abnor-
malities involving ETV6 are a relatively common finding
in B-ALL, the precise leukemogenic role of the gene in
the context of some of the aforementioned aberrations re-
mains understudied.
Case presentation
A 9-year old male with Down syndrome presented with
persistent fever and fatigue. Complete blood count re-
vealed pancytopenia (WBC 3.01×103/μL, RBC 2.87×106/
μL, platelet count 43×103/μL) with a differential of 32 %
lymphoblasts, 52 % lymphocytes, 7 % neutrophils, 4 %
monocytes, 1 % metamyelocyte, and 1 % myelocyte. Flow
cytometry on peripheral blood revealed excess abnormal
blasts comprising 22 % of total cells, and expressing
CD34, CD10, CD19, CD22, and HLA-DR. A bone marrow
biopsy showed hypercellular marrow (~90 %) and 95 % re-
placement by sheets of lymphoblasts. These findings are
consistent with a diagnosis of B-lymphoblastic leukemia,Fig. 1 Abnormal karyotype from metaphase spread seen on G-banded chr
t(2;12)(p12;p13),t(8;14)(q11.2;q32)[4]and thus, a diagnosis of B-ALL was rendered. Induction
chemotherapy was immediately started with Vincristine
and cytarabine. On day 29 post induction chemotherapy,
a bone marrow biopsy showed variably lower cellular mar-
row with approximate overall cellularity of 80 %. A follow-
up bone marrow biopsy showed minimal residual disease,
displaying a favorable response to therapy.Methods
Conventional cytogenetics
Chromosome analysis was performed on 30 metaphase
spreads from bone marrow and peripheral blood using
standard cytogenetic techniques. Karyotypes were pre-
pared using Applied Imaging CytoVision software (Ap-
plied Imaging, Genetix, Santa Clara, CA) and described
according to the International System for Human Cyto-
genetic Nomenclature (ISCN) 2013 [6].Fluorescence in situ hybridization (FISH)
FISH was performed on interphase nuclei and/or previ-
ously G-banded metaphase spreads using the following
probes acquired from Abbott Molecular (Abbott Mo-
lecular, Des Plaines, Illinois 60018):omosomes in the patient’s bone marrow: 47,XY,+21c[25]/47,idem,
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Probe Set
Vysis LSI ETV6 Dual Color, Break Apart Probe Kit
Vysis LSI IGH Dual Color, Break Apart Rearrange-
ment Probe
Vysis LSI BCR/ABL + 9q34 Tricolor, Dual Fusion
Translocation Probe
Vysis LSI MLL Dual Color, Break Apart Rearrange-
ment Probe
Vysis LSI PDGFRB (Cen) FISH Probe





Chromosome analysis of the bone marrow revealed 5
out of 30 metaphase spreads with two reciprocal translo-
cations involving 2p12 and 12p13 as well as 8q11.2 and
14q32 (Fig. 1). All 30 cells examined exhibited trisomy
21 (+21). No cytogenetically normal cells were observed.
The karyotype of the bone marrow of this patient was
described as: 47,XY,+21c[25]/47,idem,t(2;12)(p12;p13),
t(8;14)(q11.2;q32)[5].
Fluorescence in situ hybridization (FISH)
FISH analysis on interphase nuclei using the Vysis LSI
ETV6/RUNX1 ES Dual Color Translocation Probe Set
revealed 3 signals corresponding to ETV6 in 50.7 %
(152/300) of the nuclei examined, suggesting a potential
ETV6 (12p13) gene rearrangement (Fig. 2). All 300Fig. 2 FISH studies on interphase nuclei using Vysis LSI ETV6/RUNX1
Dual Color, Extra Signal Probe reveal 3 signals for ETV6 in 50.7 %
(152/300) of the nuclei examinednuclei examined exhibited 3 signals corresponding to
RUNX1 (21q22), consistent with the constitutional gen-
etic makeup of this patient (Down syndrome). FISH on
previously G-banded metaphase spreads using the Vysis
LSI ETV6 Dual Color, Break Apart Probe Kit revealed a
fusion signal (F) corresponding to an intact ETV6 gene
on the normal chromosome 12 and a split signal (1R1G)
corresponding to a rearranged ETV6 gene, with a red
signal (5′/telomeric region of ETV6) on the derivativeFig. 3 FISH on previously G-banded metaphase spreads using Vysis
LSI ETV6 Dual Color, Break Apart Probe Kit reveal a monoallelic split
signal. a DAPI image. b Inverted DAPI image
Fig. 4 FISH studies using Vysis LSI IGH Dual Color, Break Apart Rearrangement Probe on interphase nuclei showed a monoallelic split signal in
89.6 % (269/300) of the nuclei examined and biallelic split signals in 6.7 % (20/300) of the nuclei examined
Fig. 5 FISH on a previously G-banded metaphase spread using Vysis
LSI IGH Dual Color, Break Apart Rearrangement Probe revealed a
monoallelic split signal. a DAPI image. b Inverted DAPI image
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gion of ETV6) on the derivative chromosome 12, ultim-
ately confirming the t(2;12) observed by conventional
cytogenetic analysis (Fig. 3).
FISH analysis on interphase nuclei using the Vysis LSI
IGH Dual Color, Break Apart Rearrangement Probe re-
vealed two abnormal clonal populations (Fig. 4). The first
clone showed one fusion signal and one split signal
(1F1R1G) and was observed in 269/300 (89.7 %) of the nu-
clei examined. The second clone showed two split signals
(2R2G) and was observed in 20/300 (6.7 %) of the nuclei
examined. The former suggests a rearrangement involving
one IGH@ gene with the other remaining intact (monoalle-
lic), and the latter suggests rearrangements of both IGH@
genes (biallelic). FISH on previously G-banded metaphase
spreads also revealed the former signal pattern (1F1R1G)
consisting of a fusion signal and a split signal (1F1R1G),
with the fusion signal corresponding to an intact IGH@
gene on the normal chromosome 14, the red signal (3′/
telomeric region of the IGH@ gene) on the derivative
chromosome 8, and the green signal (5′/centromeric region
of the IGH@ gene) on the derivative chromosome 14, ul-
timately confirming the t(8;14) observed by conventional
cytogenetic analysis (Fig. 5). No metaphase spreads bear-
ing a second 14q32 rearrangement were observed by con-
ventional cytogenetic analysis, and we were thus not able
to detect or localize the latter signal pattern (2R2G; two
split signals) by metaphase FISH.
Analysis using other probes did not reveal any add-
itional abnormal signal patterns. This constellation of re-
sults was described as follows:
nuc ish(ETV6, RUNX1)x3[152/300]/(ETV6x2, RUNX
1x3)[148/300].
nuc ish(IGH@x2)(3′IGH@ sep 5′IGH@x1)[269/300]/
(IGH@x2)(3′IGH@ sep 5’IGH@x2)[20/300]
nuc ish(ASS1, ABL1, BCR)x2[300]





The cytogenetic findings in this case highlight a unique
combination of rearrangements that has not been previ-
ously described in B-ALL. The t(8;14)(q11.2;q32) is a re-
current translocation in B-ALL that generally causes
exchange of the regulatory regions of the IGH@ gene
and the CEBPD gene, placing CEBPD in close proximity
to the regulatory regions of IGH@ and resulting in its
overexpression [7]. Although it is relatively rare in the
general population, this translocation is more frequent
in Down syndrome-associated ALL (DS-ALL) and is as-
sociated with a B-cell precursor immunophenotype and
an intermediate prognosis [2, 8, 9]. It has also been
shown to be associated with a number of secondary cyto-
genetic abnormalities, including der(14)t(8;14)(q11.2;q32),
t(9;22)(q11.2;q34), +21, +X, and +14, although patients
with Down syndrome and t(8;14)(q11.2;q32)-positive ALL
generally do not bear a concomitant Philadelphia chromo-
some [2].
The t(2;12)(p12; p13) is a recurrent, albeit rare, trans-
location in cyclin D1-negative mantle cell lymphoma
(MCL). In these cases, it involves the IGK (2p12) and
CCND2 (12p13) genes, and results in overexpression of
CCND2 due to the placement of the CCND2 gene near
the regulatory regions of the IGK gene [10]. However, in
our case, FISH analysis using both a break apart probe
and a dual color translocation probe specific to the
ETV6 gene, which is also located at the 12p13 band,
confirmed that the t(2;12)(p12;p13) we observed inv-
olves the ETV6 gene, and not CCND2. Additionally,
since both ETV6 and CCND2 localize to 12p13, we con-
firmed that the ETV6 break apart probe (Vysis LSI
ETV6 Dual Color, Break Apart Probe Kit) we utilized in
our analysis bears no overlap with the CCND2 gene,
minimizing the possibility of a false-positive result. The
break apart probe we utilized spans chr12: 11321260–
12578058, whereas the CCND2 gene spans chr12:
4382902–4414522. We queried the Mitelman Database
of Chromosome Aberrations and Gene Fusions in Cancer
for cases of B-ALL bearing a t(2;12)(p11–p13; p12–p13)
and were only able to identify seven cases in addition to
our case, indicating that it is an extremely rare cytogen-
etic abnormality in B-ALL (Table 1). None of these
cases included corresponding molecular analysis of
ETV6, so the involvement of the gene in the reported
cases is not known. Thus, to the best of our knowledge,
this is the first reported case of B-ALL bearing a
t(2;12)(p12;p13) with ETV6 involvement confirmed by
molecular analysis. Of note, each of the previouslyreported cases and our case occurred in pediatric pa-
tients, and five out of eight of the cases carried chromo-
some 21 abnormalities, including constitutional and/or
acquired +21 and i(21q).
ETV6 is able to promote leukemogenesis via a variety of
mechanisms. Most commonly, ETV6 is involved in trans-
locations with partner genes that encode protein tyrosine
kinases or transcription factors, leading to deregulation of
signaling pathways essential to hematopoiesis via gener-
ation of fusion genes or aberrant activation of proto-
oncogenes [3]. Additionally, most evidence supports the
notion that ETV6 functions as a tumor suppressor gene.
For example, in cases where one allele of ETV6 is involved
in a translocation, there is often a concomitant deletion of
the other, non-rearranged allele [3]. Additionally, de-
creased or absent ETV6 expression has been observed in
cases that don’t bear a deletion of ETV6. Finally, point
mutations leading to loss of function of ETV6 have also
been observed [3]. These lines of evidence suggest that the
t(2;12)(p12; p13) in our case is likely a translocation in-
volving ETV6 and an unknown partner gene on the short
arm of chromosome 2 leading to aberrant activation of a
protein tyrosine kinase pathway or a proto-oncogene
encoded by that unknown partner gene. Alternatively, this
rearrangement could result in loss of function of ETV6
without affecting or involving a partner gene, which has
also been shown to contribute to leukemogenesis [3].
However, two reported cases – one case of myelodys-
plastic syndrome and one case of B-ALL – showed amp-
lification of the ETV6 gene via the generation of
homogeneously staining regions (hsr) on the short arm
of chromosome 12 [4, 5]. In both of these cases, further
molecular analysis confirmed that the homogeneously
staining regions consisted primarily of ETV6 gene ma-
terial, confirming the amplification, and immunohisto-
chemical analysis confirmed overexpression of ETV6
compared to case-matched controls [4, 5]. Furthermore,
no additional mutations involving ETV6 that are known
or predicted to result in its loss of function were ob-
served in these cases. These two cases provide evidence
against the hypothesis that ETV6 functions exclusively
as a tumor suppressor gene and suggests that in certain
contexts, it can function as an oncogene via its overex-
pression, a rare phenomenon that has been observed in
other genes such as the Wilms tumor 1 (WT1) gene
[11]. Because the t(2;12)(p12; p13) observed in MCL in-
volves overexpression of CCND2 due to placement of
the gene near the regulatory regions of IGK, it is possible
that in our case, a similar mechanism could result in
overexpression of ETV6 in the context of this transloca-
tion due to the placement of ETV6 near the regulatory
regions of IGK. Additionally, Lu et al. reported the first
case of B-ALL bearing a t(12;14)(p13;q32) involving
ETV6 and IGH@ confirmed by metaphase FISH using
Table 1 Cases of B-ALL bearing a t(2;12)(p11–p13;p12–p13) observed by conventional cytogenetic analysis
Age/Sex Karyotype Reference
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tions involving ETV6 and immunoglobulin genes can
occur in B-cell neoplasias [12]. However, such immuno-
globulin translocations can also result in mutation of the
partner gene in addition to aberrant expression, which
can affect the wild-type function of a tumor suppressor
gene [13]. Unfortunately, due to limited sample material,
we were not able to conduct further molecular or func-
tional analysis of this case to determine the precise na-
ture of the t(2;12) and the role of ETV6 in the evolution
of this malignancy.
The variation of abnormalities of the IGH@ and ETV6
genes and the variation in the frequencies of these abnor-
malities as detected by interphase FISH provides evidence
for an underlying cytogenetic evolution in the development
of this malignancy. First of all, clones bearing a monoallelic
IGH@ rearrangement, evidenced by a 1F1R1G signal pat-
tern by interphase FISH using an IGH@ break apart probe,
were observed in 89.7 % of interphase nuclei analyzed.
Conversely, only 6.7 % of cells showed evidence of biallelic
IGH@ rearrangements (2R2G) using the same probe andFig. 6 Two most likely mechanisms for the cytogenetic evolution of this m
evolution50.7 % of interphase nuclei showed evidence of an ETV6
rearrangement when analyzed with a dual color, dual fusion
translocation probe, suggesting that a monoallelic IGH@
rearrangement, caused by t(8;14)(q11.2;q32), was the pri-
mary cytogenetic abnormality in this malignancy. Because
we were not able to detect biallelic 14q32 rearrangements
by conventional cytogenetic analysis but were able to
observe both a monoallelic t(8;14)(q11.2;q32) and t(2;12)
(p12;p13) in the same metaphase spread, the evolution of
this malignancy likely happened via one of two mecha-
nisms: (1) acquisition of a primary t(8;14), followed by
t(2;12) in the same clone, followed by an additional IGH@
rearrangement in the same clone or (2) acquisition of a pri-
mary t(8;14), followed by t(2;12) in one clone and an add-
itional IGH@ rearrangement in a different clone (Fig. 6).
The former mechanism, depicted in Fig. 6a, would result in
a linear cytogenetic evolution such that a clonal population
would exist that bears all three abnormalities observed in
this case: a t(8;14), a t(2;12), and an additional IGH@ re-
arrangement. Conversely, the latter mechanism, depicted in
Fig. 6b, would result in a divergent cytogenetic evolutionalignancy. (a) linear cytogenetic evolution (b) divergent cytogenetic
Tirado et al. Biomarker Research  (2015) 3:11 Page 7 of 7such that one clonal population would bear a t(8;14), a
t(2;12), and no additional IGH@ rearrangement and the
other would bear a t(8;14) and an additional IGH@ re-
arrangement, but not a t(2;12). It is important to note that
because we did not observe biallelic 14q32 rearrangements
in any metaphase spreads by conventional cytogenetic ana-
lysis or metaphase FISH, the additional IGH@ rearrange-
ment could be due to an additional t(8;14)(q11.2; q32) or
an IGH@ rearrangement involving a different gene or locus.
Due to the relatively low frequency of the clone bearing
biallelic IGH@ rearrangements, it is more likely that this
malignancy evolved via the former, linear mechanism, al-
though both possibilities must be considered.
Among all reported cases of t(8;14)(q11.2; q32)-ALL, only
one case, reported by Harrison et al., was found to bear a
concomitant cytogenetic abnormality involving the 12p13
locus, described as follows: 47, XX, t(8;14)(q11; q32),
del(12)(p12p13),+21c. Further FISH studies confirmed both
a monoallelic IGH@ rearrangement and a monoallelic
ETV6 deletion [14]. It is evident that the involvement of cy-
togenetically detectable abnormalities involving ETV6 in
the evolution of t(8;14)(q11.2; q32)-ALL is an extremely
rare occurrence that presents a number of questions re-
garding molecular mechanisms and clinical implications
that remain understudied. We emphasize the importance
of utilizing both conventional cytogenetic and molecular
genetic tools to elucidate relevant abnormalities and mo-
lecular mechanisms in such cases, ultimately to determine
the clinical implications of rare cytogenetic abnormalities in
pediatric ALL such as those presented in this case. In sum-
mary, this case provides insight into a novel translocation
involving ETV6 as well as potentially unique and under-
studied mechanisms of clonal evolution in pediatric B-ALL
that warrant further investigation.
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